

A bill for an act

relating to insurance; limiting excessive co-payments on drugs to treat multiple sclerosis; proposing coding for new law in Minnesota Statutes, chapter 62Q.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1. **[62Q.528] MULTIPLE SCLEROSIS DRUGS; CO-PAYMENTS LIMITED.**

(a) For purposes of this section, "multiple sclerosis drug" means a drug that is approved by the federal Food and Drug Administration for the treatment of multiple sclerosis.

(b) No health plan, as defined in section 62Q.01, subdivision 3, may assess a co-payment in excess of \$50 per 30-day supply of a multiple sclerosis drug.

(c) Paragraph (b) does not apply if the multiple sclerosis drug has a less expensive generic equivalent approved by the federal Food and Drug Administration for treatment of multiple sclerosis which the patient's treating physician for multiple sclerosis has determined is equally safe and effective for the patient.

EFFECTIVE DATE. This section is effective August 1, 2009, and applies to health plans issued, renewed, or continued as defined in section 60A.02, subdivision 2a, on or after that date.